Evidence map›Paper›PMID 34389295›Full record

ArticleChest2021

Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study.

Katherine Callaway Kim, Mina Tadrous, Sandra L Kane-Gill, Ian J Barbash, Scott D Rothenberger, Katie J Suda

Abstract read
In one paragraph

Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. EFAS/EAN survey on the influence of the COVID-19 pandemic on European clinical autonomic education and research.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023
    Article
  3. Article
  4. COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katherine Callaway KimDepartment of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA; Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. Electronic address: KAC377@pitt.edu.
Mina TadrousLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Women's College Research Institute, Toronto, ON, Canada.
Sandra L Kane-GillSchool of Pharmacy, University of Pittsburgh, Pittsburgh, PA.
Ian J BarbashClinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA; Department of Medicine, Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA.
Scott D RothenbergerDepartment of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA.
Katie J SudaDepartment of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA; Center of Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA.

Funding

AHRQ HHS K08 HS025455
6 · The paper itself

Abstract

backgroundDrug supply disruptions have increased during the COVID-19 pandemic, especially for medicines used in the ICU. Despite reported shortages in wealthy countries, global analyses of ICU drug purchasing during COVID-19 are limited. RESEARCH QUESTION: Has COVID-19 impacted global drug purchases of first-, second-, and third-choice agents used in intensive care? STUDY DESIGN AND

methodsWe conducted a cross-sectional time series study in a global pharmacy sales dataset comprising approximately 60% of the world's population. We analyzed pandemic-related changes in units purchased per 1,000 population for 69 ICU agents. Interventional autoregressive integrated moving average models tested for significant changes when the pandemic was declared (March 2020) and during its first stage from April through August 2020, globally and by development status.

resultsRelative to 2019, ICU drug purchases increased by 23.6% (95% CI, 7.9%-37.9%) in March 2020 (P < .001) and then decreased by 10.3% (95% CI, -16.9% to -3.5%) from April through August (P = .006). Purchases for second-choice medicines changed the most, especially in developing countries (eg, 29.3% increase in March 2020). Despite similar relative changes (P = .88), absolute purchasing rates in developing nations remained low. The observed decrease from April through August 2020 was significant only in developed countries (-13.1%; 95% CI, -17.4% to -4.4%; P < .001). Country-level variation seemed unrelated to expected demand and health care infrastructure.

interpretationPurchases for intensive care medicines increased globally in the month of the COVID-19 pandemic declaration, but before peak infection rates. These changes were most pronounced for second-choice agents, suggesting that inexpensive, generic medicines may be purchased more easily in anticipation of pandemic-related ICU surges. Nevertheless, disparities in access persisted. Trends seemed unrelated to expected demand, and decreased purchasing from April through August 2020 may suggest overbuying. National and international policies are needed to ensure equitable drug purchasing during future pandemics.

Indexed as

Critical CareDeveloped CountriesDeveloping CountriesHealth ExpendituresPharmaceutical PreparationsAdrenal Cortex HormonesCardiovascular AgentsCentral Nervous System AgentsCOVID-19Cross-Sectional StudiesHumansInterrupted Time Series AnalysisAdrenal Cortex HormonesCardiovascular AgentsCentral Nervous System AgentsPharmaceutical PreparationsCOVID-19critical caredrugsglobal healthICU

Identifiers

PMID34389295
PMCPMC8421073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.